RISING PHARMA HOLDINGS INC — Repaglinide Importer Profile
Pharmaceutical Importer · #3 buyer for Repaglinide · $1.4M import value · 67 shipments · UNITED STATES · DGFT Verified
RISING PHARMA HOLDINGS INC is the #3 importer of Repaglinide from India with $1.4M in import value and 67 verified shipments. RISING PHARMA HOLDINGS INC holds a 6.7% market share in Repaglinide imports based in UNITED STATES. The company sources from 1 verified supplier across 44 formulations shipped to 1 country. Overall, RISING PHARMA HOLDINGS INC imports 18 pharmaceutical products worth $87.0M across 11 therapeutic categories.
RISING PHARMA HOLDINGS INC — Repaglinide Import Profile: Suppliers, Formulations & Sources
Who Actually Supplies Repaglinide to RISING PHARMA HOLDINGS INC?
Verified from 67 customs shipment records
| Supplier | Value | Shipments | % Share |
|---|---|---|---|
| AUROBINDO PHARMA LIMITED | $1.4M | 67 | 100.0% |
RISING PHARMA HOLDINGS INC sources Repaglinide from 1 verified Indian supplier based on 67 customs records. The primary supplier is AUROBINDO PHARMA LIMITED accounting for 100.0% of imports.
How Does RISING PHARMA HOLDINGS INC Compare to Nearest Repaglinide Importers?
Buyers ranked immediately above and below #3 by import value
| # | Buyer | Country | Import Value | Shipments | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | AUROLOGISTICS LLC (AUROBINDO PHARMA | UNITED STATES | $511.2K | 14 | $36.5K |
| 3 | RISING PHARMA HOLDINGS INC ★ | UNITED STATES | $463.1K | 16 | $28.9K |
| 4 | AUROLOGISTICS LLC(AUROBINDO PHARMA | UNITED STATES | $461.1K | 14 | $32.9K |
| 5 | RISING PHARMA HOLDINGS, INC. ,. ★ | UNITED STATES | $452.3K | 14 | $32.3K |
RISING PHARMA HOLDINGS INC ranks #3 among 112 Repaglinide importers from India. Average shipment value of $28.9K compared to the market average of $41.1K. The closest competitors by value are AUROLOGISTICS LLC (AUROBINDO PHARMA and AUROLOGISTICS LLC(AUROBINDO PHARMA.
Where Does RISING PHARMA HOLDINGS INC Import Repaglinide To?
Destination countries from 67 verified shipments
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $1.4M | 67 | 100.0% |
RISING PHARMA HOLDINGS INC imports Repaglinide to 1 country. The primary destination is UNITED STATES receiving 100.0% of shipments worth $1.4M.
What Repaglinide Formulations Does RISING PHARMA HOLDINGS INC Import?
| Formulation | Value | Shipments |
|---|---|---|
| REPAGLINIDE TABLETS 1 MG 21120X100'S | $77.8K | 3 |
| REPAGLINIDE TABLETS 0.5 MG (62760X100'S)NOS | $68.4K | 3 |
| REPAGLINIDE TABLETS 2 MG (20760X100'S) | $63.1K | 4 |
| REPAGLINIDE TABLETS 2 MG (REPAGLINIDE TABLETS USP 2 MG) 100'S | $63.0K | 3 |
| REPAGLINIDE TABLETS 1 MG (63120X100'S) | $50.0K | 1 |
| REPAGLINIDE TABLETS 2 MG 42360X100 S | $50.0K | 1 |
| REPAGLINIDE TABLETS 1 MG (44520X100'S) | $50.0K | 1 |
| REPAGLINIDE TABLETS 0.5 MG (41700 X 100' | $45.8K | 1 |
| REPAGLINIDE TABLETS 0.5 MG 41760X100'S | $45.4K | 1 |
| REPAGLINIDE TABLETS 2 MG (29880X100'S) | $45.4K | 1 |
RISING PHARMA HOLDINGS INC imports 44 distinct Repaglinide formulations from India. The top formulation is REPAGLINIDE TABLETS 1 MG 21120X100'S with 3 shipments worth $77.8K.
Regulatory Requirements: Importing Repaglinide into United States
What RISING PHARMA HOLDINGS INC and other importers must comply with to import Repaglinide from India
Regulatory Authority
U.S. Food and Drug Administration (FDA)
Approval Process for Generic Repaglinide
Abbreviated New Drug Application (ANDA) for generic drugs, requiring bioequivalence studies and compliance with 21 CFR. Indian manufacturing sites must pass FDA pre-approval inspection.
Typical timeline: 10–18 months for ANDA approval
GMP Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA prior to approval
Import Licence & Documentation
Drug Listing with FDA; Import Alert screening; Customs entry via FDA PREDICT system
Labeling & Packaging
US-specific labeling per 21 CFR 201 including NDC number, lot, expiry, dosage in English
Note: Subject to FDA Import Alerts and Automatic Detention if facility has open Form 483 observations.
Regulatory information is provided for general reference based on publicly available FDA guidelines for pharmaceutical imports. Requirements may vary by specific drug formulation, dosage form, and therapeutic classification. Importers should consult directly with FDA or qualified regulatory affairs professionals for case-specific guidance.
Who Are the Top Buyers of Repaglinide from India and How Much Does RISING PHARMA HOLDINGS INC Import?
India exported $4.6M worth of Repaglinide through 819 shipments from 41 suppliers to 36 countries, serving 112 buyers globally. RISING PHARMA HOLDINGS INC imports $1.4M of this total, accounting for 6.7% of India's Repaglinide exports with 67 shipments from UNITED STATES. This is verified from 67 customs shipment records covering 44 distinct formulations.
What Is the Average Order Value for RISING PHARMA HOLDINGS INC's Repaglinide Imports?
RISING PHARMA HOLDINGS INC's average Repaglinide order value is $20.8K per consignment, based on 67 shipments totaling $1.4M. RISING PHARMA HOLDINGS INC is based in UNITED STATES and ranks #3 among all Repaglinide importers from India by value. The company sources from 1 verified supplier in India.
Who Supplies Repaglinide to RISING PHARMA HOLDINGS INC?
RISING PHARMA HOLDINGS INC sources Repaglinide from 1 verified Indian supplier: AUROBINDO PHARMA LIMITED ($1.4M, 100.0%). This is based on 67 customs records.
How Does RISING PHARMA HOLDINGS INC Compare to Other Repaglinide Importers?
RISING PHARMA HOLDINGS INC ranks #3 among 112 Repaglinide importers from India with a 6.7% market share. The top 3 importers are AUROLOGISTICS LLC (AUROBINDO PHARMA ($511.2K), RISING PHARMA HOLDINGS INC ($463.1K), AUROLOGISTICS LLC(AUROBINDO PHARMA ($461.1K). RISING PHARMA HOLDINGS INC processed 67 shipments from UNITED STATES.
About RISING PHARMA HOLDINGS INC
RISING PHARMA HOLDINGS INC imports 18 products worth $87.0M. Beyond Repaglinide, top products include Gabapentin, Furosemide, Ondansetron, Pioglitazone, Escitalopram. View the complete RISING PHARMA HOLDINGS INC profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Repaglinide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Repaglinide shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature and HS code classification.
- 2.Buyer Identification: RISING PHARMA HOLDINGS INC matched across shipments using first-3-word normalization of the consignee field, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort buyer rankings.
- 4.Market Share: Calculated as RISING PHARMA HOLDINGS INC's capped import value divided by total capped export value for Repaglinide across all Indian exporters.
- 5.Verified Records: This page is backed by 67 individual customs records matching RISING PHARMA HOLDINGS INC importing Repaglinide, covering 44 formulations from 1 verified supplier.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 36+ countries, 112+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Repaglinide Import Data for RISING PHARMA HOLDINGS INC
Access order-level details, pricing data, supplier connections, and competitive analysis for RISING PHARMA HOLDINGS INC's Repaglinide imports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
RISING PHARMA HOLDINGS INC
Full Company Profile →
18 products · $87.0M total trade · 11 categories
RISING PHARMA HOLDINGS INC × Repaglinide
Verified from customs records
Company Overview
Top Products by RISING PHARMA HOLDINGS INC
Related Analysis
Need Detailed Import Data?
Access shipment-level records, supplier contacts, and formulation details for RISING PHARMA HOLDINGS INC.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Repaglinide. For current order-level data, contact TransData Nexus.